Clinical trial
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
NCT02392468 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 15, 2015
- Completion date
- August 10, 2017
- Enrollment
- 61 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.